论文部分内容阅读
表皮生长因子受体家族,又称HER/ERBB家族,由四个成员组成:HER1/EGFR/ERBB1、HER2/NEU/ERBB2、HER3/ERBB3和HER4/ERBB4,在肿瘤的发生发展中具有重要作用。以EGFR家族为靶点的治疗已经成为当前的研究热点,尤以HER1、HER2的研究最为深入,相应的靶向治疗药物已应用于临床。但随着时间的推移,EGFR抑制剂耐药现象逐渐出现。目前研究发现,针对HER3的靶向治疗策略可能逆转这种耐药现象。全文综述HER3在肿瘤发生发展中的角色,EGFR抑制剂耐药机制以及HER3抗体逆转EGFR抑制剂耐药的研究进展,以期为优化EGFR家族靶向治疗提供新的思路。
The family of epidermal growth factor receptors, also known as the HER / ERBB family, consists of four members: HER1 / EGFR / ERBB1, HER2 / NEU / ERBB2, HER3 / ERBB3 and HER4 / ERBB4, which play important roles in the development of tumors. The target of EGFR family therapy has become the current research focus, especially in the most in-depth study of HER1, HER2, the corresponding targeted therapies have been used in clinical. However, over time, EGFR inhibitor resistance gradually emerged. The current study found that targeted therapy strategies for HER3 may reverse this resistance phenomenon. This review summarizes the role of HER3 in tumorigenesis, the mechanism of EGFR inhibitor resistance, and the progress of HER3 antibody in reversing the drug resistance of EGFR inhibitors in order to provide a new idea for the optimal EGFR family targeting therapy.